- Home
- PALI vs SENS Comparison
PALI vs SENS Comparison
Compare PALI & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | SENS |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 301.2M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PALI | SENS |
|---|---|---|
| Price | $2.03 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $11.29 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 4.7M | 853.4K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $260,000.00 | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | 19.85 |
| 52 Week Low | $0.55 | $0.41 |
| 52 Week High | $2.86 | $8.75 |
Technical Indicators
Market Signals| Indicator | PALI | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 36.34 |
| Support Level | $1.57 | $4.79 |
| Resistance Level | $2.16 | $5.94 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 47.06 | 18.10 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.